Updates in the Treatment of Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.

An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.

Dr. Jae Park comments on the findings from the ELIANA study and tisagenlecleucel as a potential option for adults with R/R B-ALL.

Practical considerations for treatment selection in patients who progress on CAR T-Cell therapy.